R0V Stock Overview
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for R0V from our risk checks.
Revenio Group Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.92 |
| 52 Week High | €35.24 |
| 52 Week Low | €22.96 |
| Beta | 1.34 |
| 11 Month Change | -15.82% |
| 3 Month Change | -16.29% |
| 1 Year Change | 9.88% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -42.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| R0V | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -8.5% | 0.5% | 0.2% |
| 1Y | 9.9% | -6.8% | 8.5% |
Return vs Industry: R0V exceeded the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: R0V exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| R0V volatility | |
|---|---|
| R0V Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: R0V has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: R0V's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 230 | Jouni Toijala | www.reveniogroup.fi |
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; and iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; and DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.
Revenio Group Oyj Fundamentals Summary
| R0V fundamental statistics | |
|---|---|
| Market cap | €718.09m |
| Earnings (TTM) | €19.11m |
| Revenue (TTM) | €102.49m |
37.6x
P/E Ratio7.0x
P/S RatioIs R0V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R0V income statement (TTM) | |
|---|---|
| Revenue | €102.49m |
| Cost of Revenue | €30.34m |
| Gross Profit | €72.14m |
| Other Expenses | €53.04m |
| Earnings | €19.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 0.72 |
| Gross Margin | 70.39% |
| Net Profit Margin | 18.65% |
| Debt/Equity Ratio | 11.7% |
How did R0V perform over the long term?
See historical performance and comparison